Adaptation and Evaluation of a Chromogenic Test Procedure for Fibrin Monomers on a Centrifugal Analyzer by Wersch, J. W. J.
van Wersch: Chromogenic test procedure for fibrin monomers 169
J. Clin. Chem. Clin. Biochem.
Vol. 28, 1990, pp. 169-174
© 1990 Waller de Gruyter & Co.
Berlin · New York
Adaptation and Evaluation of a Chromogenic Test Procedure
for Fibrin Monomers on a Centrifugal Analyzer
By J. W. J. van Wersch
Haematological Laboratory, De Wever Hospital Heerlen, The Netherlands
(Received September 29/November 24, 1989)
Summary: We evaluated a recently introduced quantitative Chromogenic substrate test for the determination
of fibrin monomers in plasma (Coa-set FM test). The sample and reagent volume, the reaction time and the
composition of the zero standard were modified. In its optimized form the test showed good reproducibility
and an acceptable linearity range. Freezing and thawing of the samples does not cause problems. The
coefficient of correlation in the comparison of the Coa-set FM test and the Boehringer FM test was r = 0.967,
whereas the conformity was poor. The reference ranges for males and females were not significantly different,
resulting in a universal reference range of 8.4—13.2 nmol/1. In conclusion, the Coa-set FM test is, in the
modified form, a precise, quick and sensitive method, which can become a valuable tool in the early detection
of circulating fibrin monomers.
Introduction
The clotting process is a complex cascade of enzymatic
reactions catalysed by several coagulation factors.
Their successive activation leads to the generation of
thrombin, which finally induces the formation of
cross-linked fibrin (fig. 1). As can be seen from figure
1, fibrin-monomers are intermediate products in the
thrombin-catalysed formation of fibrin. The detection
of fibrin monomers produced "in vivo" is only pos-
sible "in vitro", when the production rate of the fibrin
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Fig. 1. Relevant part of coagulation cascade
monomers surpasses the velocity of the polymerisa-
tion reaction. Such conditions can be seen in clinical
situations like acute disseminated intravascular co-
agulation (1, 2), active thrombotic processes (3) and
malignancies of different origin (4).
For many years fibrin monomers have been detected
analytically usually done by the method of Godal (5).
The demonstration of fibrin monomers with the Godal
test is based upon the ability of the fibrin monomers
to form a gel with globular proteins in a 50% water-
ethanol solution, which can be assessed macroscopi-
cally. Another test was described by Lipinski (6) using
protamine sulphate for the detection of soluble fibrin
monomer complexes. The so called ethanol-gelation
test has several disadvantages:
1. interference by fibrin and fibrinogen degradation
products,
2. false positive results in samples with high fibrino-
gen levels (7),
3. the relative insensitivity of the test, and
4. the inability of the test to be made quantitative.
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An essential change for the better was achieved by
the introduction of the fibrin monomer test by Boeh-
ringer Mannheim in 1984, based upon the reaction of
soluble fibrin monomer complexes with human eryth-
rocytes coated with fibrin monomers. This method
originated from Largo et al. in 1976 (8), and it pro-
duces semi-quantitative results in form of a titre in-
dicating the last dilution with a positive test result. A
new quantitative photometric test (9) has now been
introduced by Kabi Vitrum under the name "Coaset
fibrin monomer". This is a spectrophotometric deter-
mination using a chromogenic substrate according to
the reaction scheme in figure 2. The aim of this study
was to evaluate this new product, to compare it with
the longer existing FM-test of the Boehringer Mann-
heim Corporation, and to optimize the test conditions
and test use where possible and necessary.
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Fig. 2. The reaction scheme
Materials and Methods
Reagents
The reagents used are listed in table 1.
Ins t rument
For the measurement of the photometric FM-test we used a
Cobas Bio centrifugal fast analyzer of Hoffmann La Roche
with a pre-incubation device for the proper adjustment of the
reagent temperature. For the measurements we programmed
the Cobas Bio for a type 6 analysis (two point measurement),
which means that the plasminogen as a reagent is simultane-
ously pipetted with the sample in the cuvette tray. After an
incubation time of 10 seconds the mixture of tissue-type plas-
minogen activator and substrate S 2390 is added as a starting
reagent. The instrument settings are given in table 2.
Tab. 2. Relevant instrument settings of the Cobas Bio
Temperature (°C)
Type of analysis
Wavelength (nm)
Sample volume (μΐ)
Diluent volume (μΐ)
Reagent volume (μί)
Incubation time (s)
Start reagent volume (μί)
Time of first reading (s)
Time interval (s)
Number of readings
Blanking mode
Printout mode
25.0
6
405
50
05
50
10
25
0.5
60
16
0
1
Samples
Venous blood samples were collected by drawing nine volumes
of blood into one volume of trisodium citrate (0.11 mol/1). After
centrifugation for 10 min (1600 g) at 25 °C the plasma was used
immediately, or stored at — 70 °C in plastic tubes until use then
thawed for the analysis with tap water for 5 minutes. Normal
pool plasma was obtained from 26 subjectively healthy males
and 25 females. Samples were prepared by predilution of 50 μΐ
test plasma with 2.0 ml tris buffer (20-25 °C).
Tab. 1. List of reagents
Test Reagent Composition Distributor
Coa-set FM
FM-test (Latex)
Tris buffer
Lot No. 081989KAD194 S-2390
Lot No. 071989KAD192
Plasminogen
Lot No. 0519898760051
Tissue type plasminogen activator
Lot No. 1119882887451
Fibrin monomers
Lot No. 1119888759951
FM reagent
Lot No. 8B085MAR90
FM control positive
Lot No. 8G028JAN90
FM control negative
Lot No. 8C032FEB90
Aprotinin (Trasylol®)
Normal plasma
Lot No. 8787451
CTS-Control Plasma Ν
Lot No. A511603A
Tris 0.063 mol/1, pH 8.5, 0.1 g/1 Tween 80
H-£-Val-Phe-Lys-/?NA - HC1, 2.9 mmol/1,
in 0.03 mol/1 sodium acetate buffer, pH
4.2, 0.1 g/1 Tween 80
Human Glu-Plasminogen 1.5 mg
3-3 μ§
0.5 mg
Human erythrocytes labelled with fibrin
monomers from human fibrinogen
Kabi
Boehringer
Mannheim
1000 000 U/l
Human normal plasma
Human normal plasma
Bayer
Kabi
Behring
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Methods
The tests were carried out according to the instructions of the
respective manufacturers. The measurements on the Cobas Bio,
however, were performed with one quarter of the original vol-
umes. In each series of determinations 3 standard solutions
were used: 0, 50 and 200 nmol/1. The preparation of the stock
standard (200 nmol/1) was carried out by reconstituting 10 μΐ
fibrin monomer solution with 720 μΐ freshly dissolved bovine
plasma.
Results
Reaction curves
In order to determine the optimal reaction times of
the Coa-set FM test we registrated the course of the.
reaction curves with time (fig. 3). From these plots it
can be seen, that the reaction rates became linear after
8 minutes; remarkably, even the zero standard showed
a slight absorption increase. Figure 4 shows the results
of the investigation of the relationship between the
absorption and the fibrin monomer concentration at
different reaction times.
0.8 Γ
Fibrin monomers[nmol/ l ]
200
150
100
16
Fig. 3. Absorbance versus time at different fibrin monomer
concentrations
0.8 ρ
For all times investigated, there was a satisfactory
linear relationship between the absorption and the
fibrin monomer concentration used. Only for the
shortest reaction time of 5 minutes did the absorption
increase seem too slow.
Linearity
For the investigation of the linearity we tested fibrin
monomer concentrations from 0 to 800 nmol/1. The
results are given in figure 5. As can be seen, linearity
was maintained up to 200 nmol/1.
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Fig. 5. Linearity of the test
Reproducibility
For the assessment of reproducibility we determined
the intra- and inter-assay variation, each with 10
determinations, and using both the standard and the
two pool plasmas (tab. 3). The intra-assay CV ranged,
depending on the concentration, from 1.2—4.6% for
the standards and from 1.4—5.4% for the pool plas-
mas.
Tab. 3. Intra-assay variation (n = 10)
Concentration of fibrin CV (%)
monomers (nmol/1)
Standard 1
Standard 2
Standard 3
Pool plasma 1
Pool plasma 2
X
191.4
95.2
44.8
86.7
7.4
SD
2.2
1.2
2.1
1.2
0.4
1.2
1.2
4.6
1.4
5.4
100 200
Fibrin monomers [nmol/l]
Fig. 4. Absorbance versus fibrin monomers at different reac- The inter-assay CV was 3.9 - 5.9% for the standards,
tion times and 8.0 — 15.5% for the pool plasmas (tab. 4).
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Tab. 4. Inter-assay variation (n = 10)
Concentration of fibrin CV (%)
monomers (nmol/1)
Standard 1
Standard 2
Standard 3
Pool plasma 1
Pool plasma 2
X
193.0
105.5
53.0
96.2
9.6
SD
7.5
3.3
3.1
7.7
1.5
3.9
3.2
5.9
8.0
15.5
Interference of the matrix
In the original manufacturer's instruction the stand-
ards were dissolved in bovine plasma. The manufac-
turer, however, recommended fresh frozen plasma as
the dissolution medium for the convenience of the
customers. Considering this problem, we decided to
test four plasmas as dissolution media: bovine plasma,
fresh frozen plasma (FFP), lyophilized normal plasma
and a deep frozen reference plasma. The results are
shown in figure 6. It can be seen that the variation
of the matrix causes clear shifts of the standard cali-
bration lines; especially the zero standard deviates
from a linear course in all matrices except bovine
plasma. Assuming the existence of a non-specific re-
action with the chromogenic substrate, we tried to
overcome the slight deviation by adding 10 μΐ of the
polyvalent enzyme inhibitor, aprotinin (Trasylol®,
100000 U/l) to 500 μΐ of the zero standard. The
results, shown in figure 7, show that linearity was
restored.
200
Fibrin monomers [nmol / l ]
Fig. 6. Interference of the different matrices
1 = bovine plasma
2 = fresh frozen plasma
3 = lyophilized normal plasma
4 = reference (100% of normal) plasma
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Fig. 7. Calibration curve with aprotinin (Trasylol®) added to
the zero standard
(r = 0.9984; y = 0.0031 χ + 0.04l)
The effect of freezing and thawing
Figure 8 shows the effect of freezing and thawing on
the recorded fibrin monomer concentrations. We
tested five fresh plasma samples after freezing and
thawing on five subsequent days. As shown in figure
8, the CV's are in the range of the inter-assay varia-
tions of the different fibrin monomer levels.
80J
i 60
40
1 2 3 4 ί
Number of freeze-thaw operations
Fig. 8. Effect of freezing and thawing
Sample 1: χ = 21.4, SD = 2.5, CV = 11.8%;
Sample 2: χ = 18.1, SD = 1.9, CV = 10.5%;
Sample 3: χ = 54.3, SD = 4.3, CV = 7.9%;
Sample 4: χ = 82.4, SD = 3.8, CV = 4.6%;
Sample 5: χ = 15.1, SD = 3.4, CV = 22.5%
Comparison of the "Coa-set-FM" test and
the "Boehringer FM" test
For the assessment of the correlation between both
tests we performed simultaneous determinations on
46 patient plasmas. The titre of the pseudo-latex FM
test was plotted against the Coa-set FM test. The
coefficient of correlation was 0.967, with a regression
line of y = 6.66 · χ - 48.0 (fig. 9).
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Fig. 9. Correlation between the pseudo-latex FM-test and the Fig. 10. Relationship of the diagnostic classification of both
Coa-set FM test tests
(n = 46; r = 0.9672; y = 6.66 χ - 48.0)
Reference values
For the determination of the reference values we
tested plasmas from 26 males and 25 females. The
results are shown in table 5. Only slight differences
were found between the sexes; reference values for
males were 8.2-13.9 nmol/1, for females 8.8-12.4
nmol/1. The differences were not statistically signifi-
cant (Student t-test, ρ = 0.17) and the values were
Gaussian distributed. The reference values can be
summarized for both males and females as 8.4—13.2
nmol/1.
Tab. 5. Reference ranges
Gender
Male
Female
All
Number
26
25
51
Average
nmol/1
11.06
10.59
10.8
Standard
deviation
nmol/1
1.41
0.90
1.2
Reference
ranges
nmol/1
8.23-13.88
8.79-12.40
8.4 -13.2
Diagnostic sensitivity
In figure 10 the Coa-set FM test (cut-off level 13.2
nmol/1) is compared with the Boehringer FM test
(cut-off level for neg/pos decision 10 nmol/1). Minor
discrepancies between the two methods were found
for only 4 out of 46 patient samples. Four concentra-
tions were marginally elevated according to the Coa-
set FM test, whereas the Boehringer FM test was still
negative. All other test samples would have been
classified correctly.
Discussion
On the basis of our results we now can reduce the
sample volume in the test to one quarter of that
recommended by the manufacturer, i.e. to 50 μΐ.
Moreover the reaction time can be shortened from 20
min to 10 min without affecting re reproducibility of
the test results. As shown in figures 3 and 6, there are
indications of non-specific reactions in the zero stand-
ard. In our opinion this problem can be overcome by
adding aprotinin to the zero standard, as shown in
figure 7. The reproducibility is good, with intra- and
inter-assay coefficients of variation of 1.2—5.4% and
3.2—15.5%, respectively, depending on the fibrin
monomer level. The linearity range is acceptable with
a range of 0—200 nmol/1, in relation to the upper
reference level of 13.2 nmol/1.
For an economical use of the rather expensive test
kit, it is important for sample requests to be analysed
in one series after freezing and storing at — 70 °C.
Our results show that there is no reason for not
adopting this procedure. Our investigation of the ma-
trix interference shows, that bovine plasma can be
replaced by fresh frozen plasma as a dissolution me-
dium, if aprotinin is added to the zero standard.
Although the "Coa-set FM test" and the "Boehringer
FM test" differ considerably, we obtained a good
correlation (r = 0.967) between the two methods. It
is a pity that the conformity is poor for reasons of
using both methods side by side in the laboratory.
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The ranges for males and females (8.2—13.9 nmol/1
and 8.8 — 12.4 nmol/1, respectively) were not signifi-
cantly different, resulting in the range 8.4—13.2
nmol/1 for both sexes. These values (10.8 ±1.2
nmol/1) are nearly the same as those reported by
Wiman & Ranby (9) (9.2 ± 1.9 nmol/1). They show
that fibrin monomers can be detected in healthy in-
dividuals under basic conditions, indicating that fi-
brinogen is being attacked to a very small extent by
thrombin.
Evidence for the presence of slow but continuous
conversion of fibrinogen to fibrin in healthy individ-
uals is also reported by Wiman & Ranby (9) and by
Bilezikian, Nossel & Butler (11). Some marginal notes
still should be made about the possible interference
of a2-antiplasmin and of fibrinogen degradation prod-
ucts (FDP). According to Wiman & Ranby (9) there
is some interference by a2-antiplasmin, but it can be
ignored, because of the high tissue type plasminogen
activator concentration in the test. As to the role of
the fibrinogen degradation products we again can
refer to Wiman & Ranby (9), who concluded from
their results that in patients with high fibrinogen
degradation products levels (about 2000 mg/1) only a
small influence was observed.
Finally from our results, we can conclude that the
diagnostic sensitivity of the "Coa-set FM test" shows
good agreement with that of the "Boehringer FM
test". There was slight doubt about the correct clas-
sification of only 4 out of 46 patient samples. In
conclusion, the new "Coa-set FM" test is a precise,
quick and sensitive method, which produces reliable
quantitative results.
It could therefore become a valuable tool in the early
detection of circulating fibrin monomers under dif-
ferent pathological conditions.
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